We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

September 24, 2021

Clinical Trial shift in response to COVID-19

Commentary
Sarah Ann Kikkers
&

Clinical Trial shift in response to COVID-19

The COVID-19 pandemic has devastated the world and has left significant lasting consequences on many sectors, particularly the clinical research and clinical trials industry. Clinical trials are an essential component of the drug approval process and provide vital information about a drug's safety and efficacy profile. As such, the disruption of clinical trials causes significant delays to a company's product portfolio and increases financial costs for clinical studies.  The pandemic resulted in about 80% of non COVID-19 clinical trials having to press pause or shut down causing major disruptions to the industry. Furthermore, more than 2,000 trials have been stopped since the pandemic began, highlighting the consequential effect of the COVID-19 pandemic.  

Many key stakeholders in the clinical trial sphere were affected by the pandemic. Government restrictions on travel, worldwide lockdowns, self isolation and social distancing requirements and the constant threat of infection to trial staff/participants were all major challenges faced by key stakeholders. 

A qualitative study conducted by the Tufts Center for the Study of Drug Development studied the impact of COVID-19 on clinical trial execution by collecting information from clinical operations professionals at pharmaceutical companies in the United States. 23 out of the 25 organisations involved reported some level of impact on ongoing trials due to COVID-19. 11 organisations stopped ongoing trials and enrollment for a month, particularly in trials that were considered high-risk for COVID infection such as pulmonology, immunology and cardiology. 

Patient enrollment and recruitment was greatly affected by the pandemic due to patient safety concerns and government imposed travel restrictions and lockdowns. Results from a retrospective cohort study examining more than 62,000 clinical trial activations during the pandemic found the number of studies initiated in the United States from February to May 2020 was only 57% of what is normally expected. Additionally, the requirement for social distancing and self isolation negatively impacted trials leading to staff/participant shortages.

These challenges forced clinical trial sponsors to employ other trial models such as decentralised clinical trials (DCT) and adopt digital health technologies such as telehealth visits and remote patient monitoring. Organisations such as the FDA implemented guidelines on how to continue trials during the pandemic, allowing investigators to use these digital health technologies and deliver drugs to participants' homes, or use online platforms to consent to taking part in trials.

Digital health technologies

The use of digital health technologies can alleviate many of the disruptions caused by the COVID-19 pandemic. Self isolation and social distancing requirements can be mitigated through the use of telehealth visits and remote patient monitoring. Digital health technologies such as wearables and sensors allow clinical trial investigators to collect information on a patient's heart rate variability, sleep, blood pressure and glucose monitoring to demonstrate how a treatment may be affecting them daily. The use of wearable devices and sensors makes it easier for individuals to participate in trials and gives investigators access to diverse patient populations. Additionally, using these digital technologies ensures patients and investigators remain connected at all times. According to Kaiser Associates and Intel, 70% of clinical trials will utilize some form of wearable sensors by 2025, highlighting the importance of this technology in future clinical trials.

Examples of the use of wearables in clinical research can be seen in a study published in Nature Medicine, highlighting the use of wearables to detect positive cases of COVID-19 by monitoring changes in heart rate, sleep and activity levels. Likewise, a partnership between Sonica Health and BARDA developed a wearable patch that sits at the base of the throat recording data on cough frequency/intensity, breathing effort as well as temperature and cardiac information. This allows them to detect and monitor COVID-19 infections. Therefore the acceleration of these technologies within the clinical trial sector proves valuable.


Decentralised Clinical Trials (DCT)

The popularity of decentralised and hybrid trial solutions exploded during the pandemic, particularly when the FDA promoted the use of virtual visits and remote patient monitoring. A report on DCTs during the pandemic, demonstrated a 76% increase in the use of DCTs during this period. While DCTs have many benefits for sponsors such as improved patient recruitment and retention and patient diversity, they also have many additional benefits obtained through the continuous collection of real-world data. The collection of data directly from the patient decreases the likelihood of missing data reducing variability and the collection of real-world data allows investigators and sponsors to predict adverse events and identify data anomalies in real time reducing errors. Similarly for patients, DCTs make it easier for them to participate in trials and reduce any burden associated with repeated site visits. As DCTs are a relatively new framework that may not be suitable for all trials, ICON, a clinical research organisation offers a range of services to assist and develop a solution that works specifically for your study.

With these new modern approaches come many data considerations for trial sponsors before adoption of these methods. Data surveillance, integration and interoperability of the digital health technologies is crucial, as integration of data collected from different devices can prove challenging. Furthermore, accessing data from electronic health records and other databases can have security and privacy concerns as can be seen in the recent hack of the Health Service Executive (HSE) records in Ireland. Lastly, more clarity is required from regulators on how data generated remotely through digital technologies can be used as regulatory requirements differ between countries. 

Although all these factors need to be considered in the modernization of clinical trials, the shift in focus to decentralized approaches and digital technologies proves exciting in the very tightly regulated field of clinical research and trials



We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
AI in Healthcare
AI in Healthcare
AI in Healthcare
AI in Healthcare

Masterclass: AI-based diagnostics - learnings from a real-world use case

21st October @ 9:00AM GMT

In this masterclass, Zachary Tan (Advisor at CancerAid; Venture Creation Partner at Aegis Ventures; more info here) & Lisa Zhu (Research Fellow of the Center for Eye Research Australia) will walk us through the key learnings from their latest article in Scientific Reports (Nature) on real-world AI-based screening for diabetic retinopathy in Australia. This early-stage study is one of the first globally to describe the real-world implementation of AI in healthcare.

Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology

Digital Health in Mental Health: Commercialization Models

21st October @ 10:45AM EDT

Join us in this informal conversation where we will discuss the best commercialisation models for digital companies in the mental health space. Our 75 minute sessions are guaranteed to be filled with interesting debate and great conversation.

Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices
Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.